

Special Issue

Advances in Treatment for Hepatobiliary and Pancreatic Cancers: Multi-Disciplinary Strategies and Outcome Evaluation

Message from the Guest Editors

Hepatobiliary and pancreatic (HBP) cancers often have dismal outcomes, although several breakthroughs, including targeted therapies, advances in immunoncology, and newly developed systemic treatment, are now applied clinically. With advances in medical treatment, surgery is still crucial under most circumstances and provides the best chance for curing the malignancy. In addition to surgery, improvements in other local ablation therapies may also provide therapeutic benefits. Nowadays, many multidisciplinary teams are focusing on this issue, improving the treatment outcome for patients with HBP cancers. We are pleased to invite you to contribute your work and research results to this Special Issue, which aims to improve treatment outcomes and the quality of patient care in HBP cancer management. Original research articles and reviews are welcome. Research areas of focus may include clinical, basic, and translational studies. We look forward to receiving your contributions.
Prof. Dr. Chun-Nan Yeh

Guest Editors

Prof. Dr. Chun-Nan Yeh

Chang Gung Memorial Hospital, Taipei, Taiwan

Dr. Shang-Yu Wang

GIST Team, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/144139

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)